ArticleMolecular and cellular biochemistry2026
BCYRN1 silencing alleviates cardiomyocyte inflammation and apoptosis in chronic heart failure via the miR-455-3p/BAX axis.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic heart failure (CHF) is a severe end-stage syndrome of multiple cardiovascular diseases, associated with unfavorable clinical prognosis. This study aimed to investigate the expression profile, clinical value and molecular mechanism of BCYRN1 in regulating myocardial cell injury in CHF. Quantitative real-time PCR (qRT-PCR) was applied to detect the expression level of BCYRN1. The Receiver operating characteristic (ROC) curves was used to evaluate its diagnostic performance, and Kaplan-Meier survival analysis was performed to explore the correlation between BCYRN1 and patient prognosis. Hydrogen peroxide (H₂O₂) was used to establish a cardiomyocyte injury model. CCK-8 assay, flow cytometry, ELISA, and Western blot were used to detect cell viability, the apoptosis rate, inflammatory cytokines secretion, and the proteins related to apoptosis, respectively. Dual-luciferase reporter assay was conducted to verify the molecular binding relationships. BCYRN1 and BAX were significantly upregulated, whereas miR-455-3p was downregulated in CHF patients. BCYRN1 exhibited reliable diagnostic efficacy for CHF; High BCYRN1 expression was correlated with lower 36-month survival. BCYRN1 knockdown improved cell viability, suppressed apoptosis and reduced inflammatory cytokine release in H₂O₂-treated cardiomyocytes. Mechanistic validation revealed that BCYRN1 acts as a competitive endogenous RNA (ceRNA) to sponge miR-455-3p, thereby releasing its inhibitory effect on BAX. Rescue experiments confirmed that inhibiting miR-455-3p abrogated the protective effect of BCYRN1 silencing on cardiomyocytes. Inhibiting BAX expression reversed the detrimental effects of the miR-455-3p inhibitor on cardiomyocytes. BCYRN1 may represent a potential biomarker for CHF diagnosis and prognosis. It worsens H
Indexed as
Identifiers
42536139What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.